Top Markets
Coin of the day
Vaxil Bio Ltd. Vaxil Bio Ltd.

Vaxil Bio Ltd.

VXL
株式のランク #39496
Vaxil Bio Ltd. is a biotechnology firm dedicated to discovering and developing... Vaxil Bio Ltd. is a biotechnology firm dedicated to discovering and developing innovative therapeutic agents. Its foundation lies in a unique signal peptide-based platform, which it leverages to address critical health challenges, specifically infectious diseases and various cancers. The company's primary therapeutic candidate, ImMucin, has successfully advanced through Phase I/II clinical trials as a potential treatment for multiple myeloma. Beyond ImMucin, Vaxil Bio is actively developing a vaccine/treatment for tuberculosis, as well as a vaccine targeting coronavirus (COVID-19). Strategic alliances bolster its research efforts; Vaxil Bio collaborates with The Tel Aviv Sourasky Medical Center on a research initiative to create a peptide-based COVID-19 vaccine. Furthermore, it holds a Cooperative Research and Development Agreement with the U.S. Army Medical Research Institute of Infectious Diseases to assess CorVax's efficacy in preventing COVID-19 in murine models. Established in 2006, the company's operations are based in Toronto, Canada.
株価
$0.1174299
最終同期: 2026-08-13
時価総額
$467.84K
変化(1日)
-8.57%
変化(1年)
1.38%
CA
取引 Vaxil Bio Ltd. (VXL)

カテゴリー

Vaxil Bio Ltd.(VXL)の配当利回りの履歴
Vaxil Bio Ltd.(銘柄コード: VXL)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Vaxil Bio Ltd.(VXL)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)